GCM
ITOS

Gladius Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Gladius Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,383
Closed -$46.1K – 338
2024
Q1 		$46.1K Buy
3,383
+252
+8% +$2.75K 0.02% 179
2023
Q4 		$34.3K Buy
3,131
+1,026
+49% +$10.2K 0.01% 251
2023
Q3 		$23.1K Buy
2,105
+813
+63% +$10.4K ﹤0.01% 333
2023
Q2 		$17.1K Sell
1,292
-424
-25% -$6.05K ﹤0.01% 311
2023
Q1 		$23.4K Sell
1,716
-119
-6% -$2.13K ﹤0.01% 316
2022
Q4 		$35.8K Buy
1,835
+249
+16% +$4.87K ﹤0.01% 264
2022
Q3 		$31K Buy
+1,586
New +$36.5K ﹤0.01% 302

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gladius Capital Management's ITOS Position: Q2 2024 in Review

Gladius Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2024, closing a stake of 3,383 shares — an estimated $46.1K sold.

Gladius Capital Management first reported a position in ITOS in Q3 2022 and held it in 7 quarters. The position peaked at $46.1K in Q1 2024. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2024.

  • Gladius Capital Management reported no remaining iTeos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Gladius Capital Management sold 3,383 iTeos Therapeutics shares in Q2 2024, an estimated $46.1K.
  • Gladius Capital Management first reported a position in iTeos Therapeutics in Q3 2022 and held it in 7 quarters.
  • Gladius Capital Management's iTeos Therapeutics position peaked at $46.1K in Q1 2024.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.